시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 위스코트-알드리치 증후군 치료 시장 보고서(2025년)
Wiskott-Aldrich Syndrome Treatment Global Market Report 2025
상품코드 : 1751182
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,170,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,918,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,666,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

위스코트-알드리치 증후군 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 7.8%의 성장률(CAGR)로 13억 3,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 표적치료에 대한 관심 증가, 진단 검사 수요 증가, 정부 이니셔티브 강화, 맞춤형 의료에 대한 수요 증가에 기인합니다. 이 기간 동안 예상되는 주요 동향으로는 기술 발전, 보다 효과적인 치료법 개발, 유전자 검사의 발전, 의학 연구의 지속적인 발전 등이 있습니다.

표적 치료제에 대한 수요 증가는 향후 위스코트-알드리치 증후군 치료제 시장의 성장을 견인할 것으로 예상됩니다. 표적 치료제는 특히 암과 같은 질병의 진행에 관여하는 특정 분자나 경로에 초점을 맞추어 건강한 세포의 손상을 최소화하면서 비정상적인 세포를 선택적으로 표적화하도록 설계되어 있습니다. 표적 치료의 부상은 특정 유전자 변이에 초점을 맞춰 치료 효과를 높이고 부작용을 줄이는 정밀 의학의 발전에 힘입어 더욱 활발해지고 있습니다. 유전자 치료와 같은 치료는 결함이 있는 WAS 유전자를 교정하여 면역 기능과 혈소판 생성을 회복시키는 것을 목표로 합니다. 예를 들어, 2024년 7월 미국 유전자 및 세포 치료학회(ASGCT)는 2024년 2분기에 76건의 유전자 치료 시험이 시작되어 전분기 대비 25% 증가했다고 보고했습니다. 그 결과, 표적 치료제에 대한 수요 증가가 위스코트-알드리치 증후군 치료제 시장 성장에 기여하고 있습니다.

위스코트-알드리치 증후군 치료제 시장의 주요 기업들은 면역체계 기능을 강화하고 감염을 관리하기 위해 면역글로불린 정맥주사와 같은 혁신적인 치료법 개발에 주력하고 있습니다. 면역글로불린 정맥주사(IVIG)는 정제된 인간 면역글로불린 G(IgG) 항체를 혈류에 직접 주입하여 면역 기능을 강화하는 치료법입니다. 수동 면역을 제공하고 면역 반응을 조절하여 면역 결핍, 자가 면역 질환, 감염 질환에 대처하는 데 사용됩니다. 예를 들어, 2024년 9월 미국 바이오 제약사 GC Biopharma USA, Inc.는 미국 식품의약국(FDA)의 승인을 받아 성인 위스코트-알드리치 증후군을 포함한 원발성 체액성 면역결핍증에 대한 10% 정맥주사용 면역글로불린 제제 ALYGLO를 미국 시장에 출시했습니다. 원발성 체액성 면역결핍증(PI) 치료를 목적으로 합니다. 풀링된 인간 혈장으로부터 제조되며, 감염과 싸우기 위한 광범위한 항체를 제공합니다. 이 제품은 미국 내 전문 약국 및 대리점 네트워크를 통해 판매될 예정이며, GC녹십자가 미국 헬스케어 분야에서 입지를 확대하는 데 있어 중요한 이정표가 될 것으로 기대됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Wiskott-Aldrich syndrome (WAS) treatment encompasses medical approaches aimed at managing this rare X-linked immunodeficiency disorder, which affects blood cells and compromises the immune system. The primary goal is to restore immune function, prevent infections, and reduce complications such as bleeding and autoimmune disorders.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The key treatment options for Wiskott-Aldrich syndrome include immunoglobulin replacement therapy, antibiotic therapy, stem cell transplantation, and gene therapy. Immunoglobulin replacement therapy helps address immune deficiencies by supplementing missing antibodies to prevent frequent infections. Diagnosis is carried out through various methods, including blood tests, genetic testing, and others. Treatment is distributed via multiple channels such as hospital pharmacies, retail pharmacies, online pharmacies, and more. It is utilized by a range of end users, including hospitals, research institutes, and specialty clinics.

The wiskott-aldrich syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides wiskott-aldrich syndrome treatment market statistics, including the wiskott-aldrich syndrome treatment industry global market size, regional shares, competitors with the wiskott-aldrich syndrome treatment market share, detailed wiskott-aldrich syndrome treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the wiskott-aldrich syndrome treatment industry. This wiskott-aldrich syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The wiskott-aldrich syndrome treatment market size has grown strongly in recent years. It will grow from$0.91 billion in 2024 to $0.99 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth during the historic period can be attributed to the rising incidence of genetic disorders, increased awareness among patients, a growing number of clinical studies, and the higher prevalence of Wiskott-Aldrich syndrome.

The wiskott-aldrich syndrome treatment market size is expected to see strong growth in the next few years. It will grow to$1.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period can be attributed to a growing focus on targeted therapies, an increased demand for diagnostic tests, more government initiatives, and a rising demand for personalized medicine. Key trends expected during this period include technological advancements, the development of more effective therapies, progress in genetic testing, and ongoing advancements in medical research.

The growing demand for targeted therapies is expected to drive the expansion of the Wiskott-Aldrich syndrome treatment market in the future. Targeted therapies are designed to focus on specific molecules or pathways involved in disease progression, especially in conditions such as cancer, to selectively target abnormal cells while minimizing damage to healthy cells. The rise of targeted therapies is fueled by advancements in precision medicine, which improves treatment effectiveness by focusing on specific genetic mutations and reducing side effects. Treatments such as gene therapy aim to correct the defective WAS gene, restoring immune function and platelet production, which in turn improves patient outcomes and decreases reliance on lifelong therapies. For example, in July 2024, the American Society of Gene and Cell Therapy (ASGCT), a U.S.-based professional organization, reported that in the second quarter of 2024, 76 gene therapy trials were initiated, marking a 25% increase compared to the previous quarter. As a result, the growing demand for targeted therapies is contributing to the growth of the Wiskott-Aldrich syndrome treatment market.

Leading companies in the Wiskott-Aldrich syndrome treatment market are focusing on the development of innovative therapies, such as intravenous immune globulin, to enhance immune system function and manage infections. Intravenous immune globulin (IVIG) is a treatment that delivers purified human immunoglobulin G (IgG) antibodies directly into the bloodstream, boosting immune function. It is used to address immune deficiencies, autoimmune diseases, and infections by providing passive immunity and regulating immune responses. For example, in September 2024, GC Biopharma USA, Inc., a U.S.-based biopharmaceutical company, launched ALYGLO, a 10% intravenous immune globulin liquid, in the U.S. market. Approved by the Food and Drug Administration (FDA), this product is designed to treat primary humoral immunodeficiency (PI) conditions, including Wiskott-Aldrich syndrome in adults. Manufactured from pooled human plasma, it provides a broad range of antibodies to combat infections. The product is available through a network of specialty pharmacies and distributors across the U.S., marking a key milestone for GC Biopharma in expanding its presence in the U.S. healthcare sector.

In June 2024, Frazier Healthcare Partners, a U.S.-based private equity and venture capital firm, acquired BioMatrix Specialty Infusion Pharmacy for an undisclosed sum. This acquisition is aimed at expanding Frazier Healthcare Partners' footprint in the growing home infusion market by establishing a national, patient-centered platform. BioMatrix Specialty Infusion Pharmacy, a U.S.-based company, provides specialty infusion services for treating Wiskott-Aldrich syndrome, including immunoglobulin therapy and in-home support.

Major players in the wiskott-aldrich syndrome treatment market are Pfizer Inc., Boston Children's Hospital, Grifols S.A., The Children's Hospital of Philadelphia, Seattle Children's Research Institute, CSL Behring LLC,GC Biopharma USA Inc., St. Jude Children's Research Hospital, Great Ormond Street Hospital, Octapharma AG, Bio Products Laboratory Limited, ADMA Biologics Inc., Ospedale San Raffaele - Milano, Mary Ann Libert Inc, Orchard Therapeutics plc, Genethon, Sage Therapeutics Inc., Yposkesi, and Telethon Foundation.

North America was the largest region in the wiskott-aldrich syndrome treatment market in 2024. The regions covered in wiskott-aldrich syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the wiskott-aldrich syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The wiskott-aldrich syndrome treatment market consists of revenues earned by entities by providing services such as genetic counseling, diagnostic services, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The wiskott-aldrich syndrome (WAS) treatment market includes sales of immunoglobulin (Ig) products, gene therapy products, and bone marrow transplants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Wiskott-Aldrich Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on wiskott-aldrich syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for wiskott-aldrich syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The wiskott-aldrich syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Wiskott-Aldrich Syndrome Treatment Market Characteristics

3. Wiskott-Aldrich Syndrome Treatment Market Trends And Strategies

4. Wiskott-Aldrich Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Wiskott-Aldrich Syndrome Treatment Growth Analysis And Strategic Analysis Framework

6. Wiskott-Aldrich Syndrome Treatment Market Segmentation

7. Wiskott-Aldrich Syndrome Treatment Market Regional And Country Analysis

8. Asia-Pacific Wiskott-Aldrich Syndrome Treatment Market

9. China Wiskott-Aldrich Syndrome Treatment Market

10. India Wiskott-Aldrich Syndrome Treatment Market

11. Japan Wiskott-Aldrich Syndrome Treatment Market

12. Australia Wiskott-Aldrich Syndrome Treatment Market

13. Indonesia Wiskott-Aldrich Syndrome Treatment Market

14. South Korea Wiskott-Aldrich Syndrome Treatment Market

15. Western Europe Wiskott-Aldrich Syndrome Treatment Market

16. UK Wiskott-Aldrich Syndrome Treatment Market

17. Germany Wiskott-Aldrich Syndrome Treatment Market

18. France Wiskott-Aldrich Syndrome Treatment Market

19. Italy Wiskott-Aldrich Syndrome Treatment Market

20. Spain Wiskott-Aldrich Syndrome Treatment Market

21. Eastern Europe Wiskott-Aldrich Syndrome Treatment Market

22. Russia Wiskott-Aldrich Syndrome Treatment Market

23. North America Wiskott-Aldrich Syndrome Treatment Market

24. USA Wiskott-Aldrich Syndrome Treatment Market

25. Canada Wiskott-Aldrich Syndrome Treatment Market

26. South America Wiskott-Aldrich Syndrome Treatment Market

27. Brazil Wiskott-Aldrich Syndrome Treatment Market

28. Middle East Wiskott-Aldrich Syndrome Treatment Market

29. Africa Wiskott-Aldrich Syndrome Treatment Market

30. Wiskott-Aldrich Syndrome Treatment Market Competitive Landscape And Company Profiles

31. Wiskott-Aldrich Syndrome Treatment Market Other Major And Innovative Companies

32. Global Wiskott-Aldrich Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Wiskott-Aldrich Syndrome Treatment Market

34. Recent Developments In The Wiskott-Aldrich Syndrome Treatment Market

35. Wiskott-Aldrich Syndrome Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기